SK Biopharmaceuticals’ sales plummeted in the first quarter, compared to a year earlier, due to the base effect of a one-off income from a licensing deal last year.In a public filing on Thursday, the company said it posted 41.1 billion won ($31.8 million) sales in the first three months of 2022, a 7
LG Chem said its U.S. partner Cue Biopharma received the FDA approval to conduct a phase 1 trial of CUE-102, an anti-cancer therapy targeting the Wilms Tumor-1 (WT-1) gene.LG Chem owns the exclusive right to develop and market CUE-102 in 11 Asian countries, including Korea, China, and Japan.With the
Amgen announced its achievement in four ESG (Environmental, Social, and Governance) strategic categories in 2021 in a report.Based in the U.S., the multinational pharmaceutical firm released the 2021 ESG Report on Wednesday.The report explained how much the company moved forward in Amgen’s ESG frame
BMS Korea said that the Ministry of Food and Drug Safety has recently approved its myelofibrosis treatment Inrebic (ingredient: pedratinib) and myelodysplastic syndrome treatment Reblozyl (ingredient: ruspartercept),Inrebic received approval from regulators to treat adults with an enlarged spleen an
Roche Korea is strengthening its position in the local hepatocellular carcinoma market after receiving reimbursement for combination therapy of Tecentriq and Avastin as a first-line treatment, according to an expert Wednesday.“Tecentriq and Avastin combination therapy will bring major changes in tre
GC Cell said that it has signed a contract development and manufacturing organization (CDMO) agreement with Cellab Med to produce the latter's investigational drug for a solid cancer chimeric antigen receptor (CAR)-T treatment.GC Cell noted that this is the first development and manufacturing contra
HK inno.N has signed a contract with Dr. Reddy's Laboratories, an India-based multinational pharmaceutical company, to export finished products of K-CAB (ingredient: tegoprazan), a drug for gastroesophageal reflux disease (GERD), to seven countries.The seven countries are India, South Africa, Russia
A new drug, which proved heart and kidney protection effects in chronic kidney disease (CKD) patients accompanying type-2 diabetes, has arrived in Korea to counter well-established SGLT-2 inhibitors.On Tuesday, the Ministry of Food and Drug Safety authorized the use of Bayer’s Kerendia (ingredient:
LegoChem Bioscience said that it would start the operation of AntibodyChem Biosciences (ACB), its U.S. subsidiary in Boston.The company established ACB to develop global new drugs based on its antibody-drug conjugate (ADC) platform technology. ACB will lead global clinical development by joining the
Ferring’s Rekovelle (follitropin delta), a treatment to promote egg production in ovaries, became reimbursable when used in combination with human menopausal gonadotropin (hMG) in women receiving in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).Ferring Korea said Rekovelle got
Hanmi Pharmaceutical said that Aptose Biosciences, its American partner, has received orphan drug designation (ODD) for HM43239, an acute myeloid leukemia (AML) treatment, from the U.S. Food and Drug Administration.The company had licensed out the treatment to Aptose in November.Under the deal, Hanm
BMS’ anemia treatment Reblozyl (ingredient: luspatercept) arrived in the Korean market only two and a half years after the company completed drug development in the U.S.The Ministry of Food and Drug Safety authorized Reblozyl to treat adult anemia patients who failed an erythropoiesis-stimulating ag
Forxiga (dapagliflozin) and Jardiance (empagliflozin), the two representative SGLT-2 inhibitors, are competing not only in diabetes but cardio and renal diseases.On Thursday, AstraZeneca said Forxiga met the primary endpoint in a large-scale global phase 3 study, DELIVER, reducing the risk of cardio
Shionogi, a Japanese pharmaceutical company, halted its phase 2/3 trial of S-217622, an oral Covid-19 treatment candidate, in the Philippines.According to Philippine Health Research Registry on Monday, Shionogi updated the S-217622 phase 2/3 clinical trial status in the Philippines to “terminated” a
HLB said that its U.S. subsidiary Elevar Therapeutics has started marketing Apealea, an ovarian cancer treatment, in Germany after listing the drug on Gelbe Liste, a German drug distribution website.Elevar acquired the global rights for the drug from Vivesto, the original developers, in March 2020.
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), the second-generation antibody-drug conjugate (ADC) that showed superiority to Roche’s Kadcyla in HER2-positive breast cancer treatment, received U.S. approval for patients with metastatic HER2-positive breast cancer after one p
Hugel said on Friday that it received a clinical study report (CSR) on the phase 1 trial of HG102, a lidocaine-containing liquid botulinum toxin (BTX), on Wednesday.HG102 is made into liquid from the existing BTX in a freeze-dried powder form. It contains lidocaine hydrogen chloride, a local anesthe
The Ministry of Food and Drug Safety (MFDS) and the pharmaceutical industry are wrangling over whether the nation should allow the indirect export of botulinum toxin (BTX) products through agencies.Industry officials raised concerns that the latest controversy, sparked by the regulator’s detection o
Yuyu Pharmaceutical presented a poster study for YP-P10, its new dry eye syndrome treatment, during the 2022 ARVO (Association for Research in Vision and Ophthalmology) conference.ARVO, established in 1928, is the world's largest ophthalmology society and has 12,000 research members from over 75 cou
Sam Chun Dang Pharm has been clarifying the discussion with a Chinese pharmaceutical firm over licensing out a diabetic drug candidate repeatedly for a year. Attention is on whether the two will ink a final deal and when it will happen.“We are discussing a deal with China’s Tonghua Dongbao Pharmaceu